Antisense Oligonucleotides Market size exceeded USD 1.7 Bn in 2021, due to increasing number of patients With autoimmune disorder
The global Antisense Oligonucleotides market size was estimated to be US$ 1.7 billion in 2021 and is expected grow at a CAGR of 9.5% between 2023 to 2032.
Antisense oligonucleotides are small, single-stranded RNA or DNA fragments that can interact directly with biomolecules. Such oligonucleotides need not change the activity of proteins that are already translated, but rather act on mRNAs. These oligonucleotides are only 15-25 nucleotides in length and are intended to bind to complementary mRNA targets for destruction rather than translation into protein.
Thus, antisense oligonucleotides (ASO) could be utilized to inhibit disease processes by changing the production of a particular protein. They provide potential therapy options for a variety of medical conditions, including inherited diseases.
ASOs can mute or alter genes, disrupt overall RNA function at the cell level, and specifically target faulty genes. ASOs, which allow immune response alterations, can cure a wide spectrum of autoimmune illnesses that are currently difficult to treat with present medications.
Access the sample report: https://www.insightslice.com/request-sample/1279
Global Antisense Oligonucleotides Market Key Segments:
Based on Drugs
- Pegaptanib
- Eteplirsen
- Mipomersen
- Others
Based on Therapeutic Application
- Cancer
- Diabetes
- Ocular diseases
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy
- Hemorrhagic fever viruses
- HIV/AIDS
- Cytomegalovirus retinitis
- Others
Based on Distribution Channel
- Hospitals
- Retail Pharmacies
- Online Pharmacies
Based on Geography
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
The key players of the Global Antisense Oligonucleotides Market are:
While numerous organizations, including well-known businesses such as Pfizer, BioNTech, Moderna, and others, are working on RNA-based therapies and vaccines, a few biotech start-ups are also rising and impacting the antisense oligonucleotide market trends.
The antisense oligonucleotide sector is typically concentrated, with a few players earning a major growth share. Currently, market players in antisense oligonucleotides are significantly investing in research and development, intending to develop a strong portfolio within the next several years.
Key players in the global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., GlaxoSmithKline Plc., Gene Signal International SA., Geron Corporation, Gradalis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., Rxi Pharmaceuticals Inc and others.
Driving factors for the growth of Global Antisense Oligonucleotides Market
The fact that antisense oligonucleotides provide potential therapy options for a variety of medical illnesses influences their adoption into clinical use significantly. Furthermore, they permit the creation of therapies that impact protein targets that cannot be addressed with other targeted therapies, hence accelerating the growth of the global antisense oligonucleotide market.
They may target a specific faulty gene, disrupt the RNA activity at the cellular level, as well as silence gene expression and therefore have piqued the interest of pharmaceutical companies.
The growth of the market for antisense oligonucleotides can be linked to their assistance in changing the immune system, which allows for the treatment of a broad range of autoimmune illnesses that are now untreatable with conventional medications.
In comparison to other medications, ASOs have few adverse effects and are readily regulated. Furthermore, as opposed to other clinical therapies, Antisense Oligonucleotides are simpler to scale up to a commercial scale and have faster manufacturing processes.
The increasing number of patients with autoimmune disorders such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobulinemia, and chronic inflammatory demyelinating polyneuropathy (CIDP) will fuel the market expansion of the antisense oligonucleotides.
The number of autoimmune/chronic diseases research and development projects has expanded, and the investment in creating new and sophisticated solutions will support antisense oligonucleotide market expansion throughout the projection period.
Read more about the report inclusions: https://www.insightslice.com/antisense-oligonucleotides-market
As of now, the antisense oligonucleotides market has witnessed four FDA approvals for the treatment of diseases from different spectrums, and newer approvals are also expected.
The worldwide antisense oligonucleotides market is expected to grow due to a strong pipeline of antisense oligonucleotides and a stronger emphasis on a high number of product approvals and commercialization.
Even if the market growth of antisense oligonucleotides is not reliable, the antisense oligonucleotides market forecast is favorably impacted by the market’s leading companies and the quantity of expenditure on research and development.
Furthermore, substantial breakthroughs in the domain of antisense oligonucleotides at the pharmaceutical or clinical level are fueling the worldwide antisense oligonucleotides market. However, unlike biologics, small compounds, and gene and cell therapy, this sector has yet to be recognized as a valuable medication category and thus lacks approval relaxations which hinder progress by a small margin.
COVID-19 impact on Antisense Oligonucleotides market
The COVID-19 pandemic has also provided various chances for pharmaceutical firms to raise their research and development resources to provide treatment to critically ill patients. Furthermore, the increased activity of regulatory bodies to authorize innovative medicines has boosted the antisense oligonucleotide market growth.
Related reports:
Gene Synthesis Market: https://www.insightslice.com/gene-synthesis-market
Blood Culture Test Market: https://www.insightslice.com/blood-culture-test-market
Challenges of Global Antisense Oligonucleotides Market
Despite significant clinical advances, one of the biggest obstacles impeding the development of the global antisense oligonucleotide market is the development of delivery systems for an active oligonucleotide to the within target cells. There is currently a shortage of trained healthcare personnel that lack training for administering antisense oligonucleotide therapies.
Such inadequacies in knowledge and expertise may be limiting factors for market growth in the near future. Furthermore, the development of a new set of distinct regulatory rules is likely to impede antisense oligonucleotide market approval and sales.
Proceed to purchase: https://www.insightslice.com/buy-now/1279
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com.
Contact us:
Alex R
+1 707 736 6633
Editor Details
-
Company:
- insightSLICE
- Website:
